AK 0610
Alternative Names: AK-0610Latest Information Update: 18 Jan 2024
At a glance
- Originator Ark Biosciences
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Respiratory syncytial virus infections
Most Recent Events
- 18 Jan 2024 Ark Biosciences plans to file an IND application for Respiratory syncytial virus infections (Prevention, In children) (Ark Biosciences pipeline, January 2024)
- 03 Jan 2022 Preclinical trials in Respiratory syncytial virus infections (Prevention, In children) in China (unspecified route) (Ark Biosciences pipeline, January 2022)